Verge Genomics

Verge is a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs.

Verge uses artificial intelligence and human data to develop better drugs faster for large unmet diseases. 

Verge Genomics was founded in 2015 by Alice Zhang, and Jason Chen. The company is headquartered in South San Francisco, California.

 

Verge has built an end-to-end drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets in neuroscience.

 

Verge applies machine learning to reveal new targets from human datasets and develops drugs with greater probabilities of success using its human-centric biology and chemistry platforms.

 

Verge has further demonstrated the power of its platform by delivering a broad preclinical and discovery pipeline spanning diverse therapeutic areas, with its first program entering the clinic in 2022.

 

Verge is backed by BlackRock, DFJ, Lilly, Merck GHI, WuXi AppTec’s Corporate Venture Fund, ALS Investment Fund, Threshold, Section 32, Vulcan Capital, and others. The company raised $98M in Series B round on Dec 16, 2021. This brings Verge's total funding to $134M to date.

 

 

  • Year founded: 2015
  • Funding Info: $134M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: South San Francisco
  • State: California
  • Country: United States
Related businesses